
    
      Evaluate the safety and efficacy of paricalcitol injection with two different dosing regimens
      (currently approved dosing regimen used in the US package insert versus dosing based on a
      formula of iPTH/80 that was approved and used in the EU package insert) in Chronic Kidney
      Disease (CKD) Stage 5 subjects with secondary hyperparathyroidism receiving hemodialysis.
    
  